{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:39:11Z","timestamp":1790199551607,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Orion Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11523-019-00674-0","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T19:21:15Z","timestamp":1569871275000},"page":"527-539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Evaluation of Clinically Relevant Drug\u2013Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02200614","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Zurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hille","family":"Gieschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Graudenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Koskinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Ploeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Prien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Borghesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Petrenciuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teuvo L.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"674_CR1","unstructured":"National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer stat facts: prostate cancer. 2019. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed 16 May 2019."},{"issue":"3","key":"674_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41391-018-0121-2","volume":"22","author":"E Francini","year":"2019","unstructured":"Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, et al. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer Prostatic Dis. 2019;22(3):420\u20137. https:\/\/doi.org\/10.1038\/s41391-018-0121-2.","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"12","key":"674_CR3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S1470-2045(13)70424-8","volume":"14","author":"E Basch","year":"2013","unstructured":"Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013;14(12):1193\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(13)70424-8.","journal-title":"Lancet Oncol."},{"key":"674_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2017.03.001","volume":"55","author":"M Del Re","year":"2017","unstructured":"Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, et al. The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate\/prednisone and enzalutamide. Cancer Treat Rev. 2017;55:71\u201382. https:\/\/doi.org\/10.1016\/j.ctrv.2017.03.001.","journal-title":"Cancer Treat Rev"},{"key":"674_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3332\/ecancer.2016.611","volume":"10","author":"R Stepney","year":"2016","unstructured":"Stepney R, Lichtman SM, Danesi R. Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015. Ecancermedicalscience. 2016;10:611. https:\/\/doi.org\/10.3332\/ecancer.2016.611.","journal-title":"Ecancermedicalscience."},{"issue":"8","key":"674_CR6","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1124\/dmd.115.069096","volume":"44","author":"T Bohnert","year":"2016","unstructured":"Bohnert T, Patel A, Templeton I, Chen Y, Lu C, Lai G, et al. Evaluation of a new molecular entity as a victim of metabolic drug-drug interactions-an industry perspective. Drug Metab Dispos. 2016;44(8):1399\u2013423. https:\/\/doi.org\/10.1124\/dmd.115.069096.","journal-title":"Drug Metab Dispos"},{"key":"674_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","volume":"13","author":"B Guthrie","year":"2015","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74. https:\/\/doi.org\/10.1186\/s12916-015-0322-7.","journal-title":"BMC Med."},{"issue":"26","key":"674_CR8","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1800536.","journal-title":"N Engl J Med"},{"issue":"15","key":"674_CR9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1715546.","journal-title":"N Engl J Med"},{"issue":"1","key":"674_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bcp.13425","volume":"84","author":"GE Benoist","year":"2018","unstructured":"Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, et al. Drug-drug interaction potential in men treated with enzalutamide: mind the gap. Br J Clin Pharmacol. 2018;84(1):122\u20139. https:\/\/doi.org\/10.1111\/bcp.13425.","journal-title":"Br J Clin Pharmacol"},{"key":"674_CR11","unstructured":"Astellas Pharma US Inc. Xtandi (enzalutamide) US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203415s014lbl.pdf. Accessed 11 June 2019."},{"key":"674_CR12","unstructured":"European Medicines Agency. Summary of product characteristics: XTANDI. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf. Accessed 11 June 2019."},{"key":"674_CR13","unstructured":"European Medicines Agency. Summary of product characteristics: ERLEADA. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/erleada-epar-product-information_en.pdf. Accessed 11 June 2019."},{"key":"674_CR14","unstructured":"Janssen Ortho LLC. Erleada (apalutamide) US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210951s000lbl.pdf. Accessed 22 July 2019."},{"key":"674_CR15","unstructured":"European Medicines Agency. Xtandi CHMP assessment report. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002639\/WC500144998.pdf. Accessed 1 Oct 2018."},{"key":"674_CR16","unstructured":"European Medicines Agency. Erleada CHMP assessment report. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/erleada-epar-public-assessment-report_en.pdf. Accessed 1 Oct 2018."},{"issue":"5","key":"674_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clgc.2018.07.017","volume":"16","author":"K Fizazi","year":"2018","unstructured":"Fizazi K, Smith MR, Tombal B. Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer. Clin Genitourin Cancer. 2018;16(5):332\u201340. https:\/\/doi.org\/10.1016\/j.clgc.2018.07.017.","journal-title":"Clin Genitourin Cancer."},{"key":"674_CR18","unstructured":"US Food and Drug Administration. FDA approves darolutamide for non-metastatic castration-resistant prostate cancer. 2019. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer. Accessed 31 July 2019."},{"issue":"13","key":"674_CR19","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1815671.","journal-title":"N Engl J Med"},{"key":"674_CR20","volume-title":"Drug-drug interaction of darolutamide with cytochrome P450 and P-glycoprotein substrates: results from clinical and in vitro studies","author":"C Zurth","year":"2019","unstructured":"Zurth C, Graudenz K, Denner K, Vairlein M, Korjamo T, Fricke R, et al. Drug-drug interaction of darolutamide with cytochrome P450 and P-glycoprotein substrates: results from clinical and in vitro studies. San Francisco: ASCO Genitourinary Cancers Symposium; 2019."},{"key":"674_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-019-00577-5","author":"C Zurth","year":"2019","unstructured":"Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, et al. Drug\u2013drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019. https:\/\/doi.org\/10.1007\/s13318-019-00577-5.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"674_CR22","unstructured":"R (Version 3.1.1) Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008."},{"key":"674_CR23","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Nubeqa (darolutamide) US prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212099Orig1s000lbl.pdf. Accessed 31 July 2019."},{"issue":"2","key":"674_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.eururo.2018.09.011","volume":"75","author":"GE Benoist","year":"2019","unstructured":"Benoist GE, van Oort IM, Burger DM, Koch BCP, Mehra N, van Erp NP. The combination of enzalutamide and opioids: a painful pitfall? Eur Urol. 2019;75(2):351\u20132. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.011.","journal-title":"Eur Urol"},{"key":"674_CR25","unstructured":"US Center for Drug Evaluation and Research. NDA\/BLA clinical pharmacology and biopharmaceutics review NDA 203415 Xtandi (enzalutamide). 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203415Orig1s000ClinPharmR.pdf. Accessed 26 Sept 2018."},{"key":"674_CR26","unstructured":"US Center for Drug Evaluation and Research. NDA\/BLA multi-disciplinary review and evaluation NDA 210951 Erleada (apalutamide). 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210951Orig1s000MultidisciplineR.pdf. Accessed 26 Sept 2018."},{"issue":"15_suppl","key":"674_CR27","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1200\/JCO.2019.37.15_suppl.5025","volume":"37","author":"YaoYao Guan Pollock","year":"2019","unstructured":"Pollock Y, Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, et al. Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). J Clin Oncol. 2019;37(15_suppl):5025. https:\/\/doi.org\/10.1200\/jco.2019.37.15_suppl.5025.","journal-title":"Journal of Clinical Oncology"},{"key":"674_CR28","first-page":"1","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;3:1\u2013150.","journal-title":"Kidney Int"},{"key":"674_CR29","volume-title":"Top 100 drug interactions 2018. A guide to patient management","author":"PD Hansten","year":"2018","unstructured":"Hansten PD, Horn JR. Top 100 drug interactions 2018. A guide to patient management. 19th ed. LLP: H&H Publications; 2018.","edition":"19"},{"key":"674_CR30","unstructured":"US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. 2017. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed 15 Aug 2019."},{"key":"674_CR31","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events, version 4.03. Bethesda, MD: Cancer Therapy Evaluation Program. 2010. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed 16 Sept 2019."},{"issue":"1","key":"674_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11011-011-9274-6","volume":"27","author":"S De Gregori","year":"2012","unstructured":"De Gregori S, De Gregori M, Ranzani GN, Allegri M, Minella C, Regazzi M. Morphine metabolism, transport and brain disposition. Metab Brain Dis. 2012;27(1):1\u20135. https:\/\/doi.org\/10.1007\/s11011-011-9274-6.","journal-title":"Metab Brain Dis"},{"issue":"6","key":"674_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s40495-016-0076-8","volume":"2","author":"S Ge","year":"2016","unstructured":"Ge S, Tu Y, Hu M. Challenges and opportunities with predicting in vivo phase II metabolism via glucuronidation from in vitro data. Curr Pharmacol Rep. 2016;2(6):326\u201338. https:\/\/doi.org\/10.1007\/s40495-016-0076-8.","journal-title":"Curr Pharmacol Rep."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00674-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-019-00674-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-019-00674-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:00:37Z","timestamp":1628596837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-019-00674-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1007\/s11523-019-00674-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"30 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by Bayer HealthCare and Orion Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Shore reports personal fees from Ferring, Bayer, Amgen, Janssen, Dendreon, Tolmar, Astellas, Pfizer, AstraZeneca, Genentech\/Roche, Myovant Sciences, Merck, AstraZeneca, Bristol Meyers Squibb, and Nymox outside the submitted work. Drs. Zurth, Fricke, Gieschen, Graudenz, Ploeger, Prien, Borghesi, Petrenciuc, and Kuss report employment by and stock ownership in Bayer. Dr. Koskinen reports employment by and stock ownership in Orion. Dr. Moss reports personal fees from Akari, AstraZeneca, Bayer, Carrick Therapeutics, Debiopharm, Orphazym, Proveca, Richmond Pharmacology, and the University of Leicester outside the submitted work. Dr. Tammela reports personal fees from Janssen, and grants and personal fees from Bayer, Lidds AB, and Astellas, outside the submitted work. Dr. Verholen reports employment by Bayer. Dr. Smith reports personal fees from Amgen, Astellas, Bayer, Clovis, Gilead, Janssen, Lilly, Novartis, and Pfizer, outside the submitted work. Dr. Fizazi reports personal fees from Amgen, Astellas, AstraZeneca, Bayer, Clovis, Curevac, ESSA, Janssen, Orion Pharma, Roche\/Genentech, and Sanofi outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}